BRIEF—ICER to assess canakinumab for atherosclerosis

The US Institute for Clinical and Economic Review(ICER) yesterday announced plans to develop a report assessing the comparative clinical effectiveness and value of Swiss pharma giant Novartis’ Ilaris (canakinumab) for cardiovascular risk reduction in people with atherosclerosis.

The report is set to be reviewed during a January 2019 public meeting of the Midwest Comparative Effectiveness Public Advisory Council, one of the ICER’s three independent evidence appraisal committees.

Canakinumab was originally approved by the Food and Drug Administration in 2009 and is marketed for various rare inflammatory disorders; it is currently under review for a new indication in atherosclerosis.

An Open Input period begins today and is intended to allow stakeholders to share key information relevant to the development of the evidence report. Comments will be accepted from all interested stakeholders on either topic until July 5, 2018.

During this time, the ICER will also contact key patient groups and clinical experts to gain further insights on the patient perspective and clinical context of treatment for these conditions.